Navigation Links
Synthorx Advances Its Synthetic DNA Technology To Make Its First Full-Length Proteins Incorporating Novel Amino Acids

SAN DIEGO, Aug. 19, 2015 /PRNewswire/ -- Synthorx Inc. announced today that the company has employed its proprietary protein expression system to successfully produce proteins containing novel amino acids. Using a semi-synthetic DNA template (containing the synthetic base pair X and Y), Synthorx scientists were able to produce RNA containing X and Y, which was used with an otherwise fully natural biological system, to efficiently direct the incorporation of multiple novel amino acids at different sites in proteins.

"Synthorx has built a world class research team that has achieved a scientific milestone in record time," said Court Turner, president and co-founder of Synthorx. "By advancing our technology to this stage, we are now poised to produce proteins containing multiple novel amino acids, to fill our drug discovery pipeline as well as enable our partners in many aspects of drug development and manufacturing."

The work builds on research published in Nature last year that described the first in vivo replication of DNA containing a synthetic base pair, named d5SICSTP and dNaMTP (abbreviated X and Y). The incorporation of X and Y into DNA expands the genetic alphabet and promises to allow for site-specific incorporation of multiple, different novel amino acids into a single protein. Since the publication, Synthorx has developed and validated a protein expression system, employing its synthetic DNA technology to incorporate novel amino acids to create new full-length and functional proteins.

"The Synthorx system uses a fully natural cellular system and allows for site-specific insertion of multiple novel amino acids to create more diverse proteins with a range of properties," added Mr. Turner. "We have now shown that our synthetic base pair, X and Y, can not only be replicated in vivo but are also compatible with the natural biological machinery to enable novel protein expression."

DNA from every known species has the ability to code for or "spell" proteins that are assembled from 20 natural amino acids, based on arrangements of its four chemical bases or letters – A, T, G and C. But the DNA that Synthorx makes containing its synthetic bases, X and Y, has the potential to spell with an additional 152 novel amino acids, which could be combined to make proteins with unique properties.

"Hundreds of novel amino acids have been produced in the lab, but incorporating them into a protein in a useful and scalable manner requires an expanded genetic code," explained Mr. Turner. "With our synthetic base pair, we can add multiple different, novel amino acids at any location into a single protein. Now we can create more diverse proteins for improved drugs, diagnostics, and vaccines."

In the current work, Synthorx scientists site-specifically added novel amino acids into a regular protein. To do this, they customized the DNA that encoded for the protein by adding the synthetic base pair at specific locations. Using the Synthorx expression system, the DNA was then transcribed into messenger RNA, which was then translated into a protein of several hundred regular amino acids and one or more novel amino acids. The accurate incorporation of the novel amino acids at the intended locations was confirmed with mass spectrometry.

"When I began working on synthetic bases more than 15 years ago, the end goal was always to be able to incorporate novel amino acids into proteins in a robust manner," said Floyd Romesberg, Ph.D., Synthorx's co-founder and professor at The Scripps Research Institute. "With the ability to generate novel and diverse proteins, we have a significant opportunity to make a revolutionary leap forward in improving health by creating new medical and technological applications."

About Synthorx

Synthorx is a biotechnology company using synthetic biology to synthesize solutions for the discovery and development of novel therapeutics, diagnostics, and vaccines. With the revolutionary advancement of synthetic nucleotides that can be maintained and replicated by a single-cell organism, Synthorx is exploring the natural and evolution-directed technologies to improve drug discovery. Using synthetic nucleotides to expand the genetic alphabet, Synthorx is developing novel proteins, RNA and DNA for medical applications. Synthorx's investors include Avalon Ventures and Correlation Ventures. The company was founded based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute in La Jolla, CA.

For more information, please visit and follow on Twitter @synthorx.

Photo -


SOURCE Synthorx Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
2. Advances in Molecular Testing Offer New Hope for Lung Cancer Patients
3. SPIE Counts Advances in Sustainable Photonics on List of Solutions to Celebrate on Earth Day
4. Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
5. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
6. Latest Advances in Treatment for Alzheimers, Traumatic Brain Injury and Stroke to Be Presented at Symposium
7. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
8. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
9. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
10. EGEN, Inc. Advances a Systemically Delivered RNAi Therapeutic for the Treatment of Pulmonary Arterial Hypertension (PAH)
11. New Advances and Opportunities in Managing Pain: Translational Animal Models, New Webinar Hosted by Xtalks
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):